Ashish M. Kamat: Bladder-sparing Therapy for BCG–unresponsive NMIBC

Sabine D. Brookman-May, Professor of Urology at the Ludwig-Maximilians University of Munchen, shared a post by Ashish M. Kamat, Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at University of Texas MD Anderson Cancer Center, on X adding:

“Bladder Sparing treatment and sequencing recommendations for patients with BCG unresponsive NMIBC.

• Use the right definition for BCG unresponsiveness.
• Optimal staging needed including imaging and re-TURBT.
• Beyond available treatments counsel patients for clinical trials.”

Quoting Ashish M. Kamat’s post:

“Timely!

Just out from IBCG23 as we wrap up IBCG24:

Bladder-sparing Therapy for BCG–unresponsive NMIBC: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.”

Source: Sabine D. Brookman-May/X and Ashish M. Kamat/X

Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.

Authors: Roger Li, Patrick J. Hensley, Shilpa Gupta, Hikmat Al-Ahmadie, Marko Babjuk, Peter C. Black, Maurizio Brausi, Kelly K. Bree, Mario I. Fernández, Charles C. Guo, Amir Horowitz, Donald L. Lamm, Seth P. Lerner, Yair Lotan, Paramananthan Mariappan, David McConkey, Laura S. Mertens, Carmen Mir, Jeffrey S. Ross, Michael O’Donnell, and Ashish M. Kamat.